Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer - PubMed (original) (raw)
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer
Maider Zabala et al. J Hepatol. 2007 Dec.
Abstract
Background/aims: Hepatocellular carcinoma (HCC) often lacks curative treatment; therefore new efficient therapies are needed. In this work we aimed at evaluating the antitumor effect of interleukin-12 (IL-12)-based gene therapy on HCC occurring spontaneously in mice.
Methods: A plasmid-vector expressing IL-12 in a liver-specific and doxycycline (Dox)-inducible manner was transferred by hydrodynamic injection to the liver of L-PK/c-myc mice with HCC. IL-12 expression was induced by administering Dox (3 cycles of 1 month duration separated by 1 month rest).
Results: Dox administration increased serum IL-12 and IFN-gamma and induced tumor lymphocytic infiltration in all treated mice which was accompanied by tumor stabilization or regression in 40% of animals. The antitumor effect did not correlate with levels of IL-12 or IFN-gamma nor with the intensity of tumor mononuclear infiltration. However, tumors from non-responder mice showed more abundance of Foxp3+ regulatory T cells and higher expression of the immunosuppressive molecules PD-1, PD-L1, VEGF, CTLA-4, IDO, and IL-10 than those that responded to therapy.
Conclusions: Although long-term induction of IL-12 expression in the liver can inhibit HCC growth, the efficacy of the treatment appears to be limited by the activation of immunosuppressive mechanisms.
Similar articles
- Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model.
Yamashita YI, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T, Tanaka S, Shirabe K, Miyazaki JI, Sugimachi K. Yamashita YI, et al. Cancer Res. 2001 Feb 1;61(3):1005-12. Cancer Res. 2001. PMID: 11221826 - Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW Jr, Li D, McQuone SJ, Ralston R. O'Malley BW Jr, et al. Laryngoscope. 2005 Mar;115(3):391-404. doi: 10.1097/00005537-200503000-00002. Laryngoscope. 2005. PMID: 15744147 Clinical Trial. - Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G. Komita H, et al. J Hepatol. 2006 Nov;45(5):662-72. doi: 10.1016/j.jhep.2006.05.018. Epub 2006 Jul 7. J Hepatol. 2006. PMID: 16935390 - Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
Chang CY, Lee J, Kim EY, Park HJ, Kwon CH, Joh JW, Kim SJ. Chang CY, et al. BMC Cancer. 2007 May 23;7:87. doi: 10.1186/1471-2407-7-87. BMC Cancer. 2007. PMID: 17519043 Free PMC article. - Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H. Tang L, et al. Gene Ther. 2007 Aug;14(16):1226-34. doi: 10.1038/sj.gt.3302959. Epub 2007 Jun 28. Gene Ther. 2007. PMID: 17597794
Cited by
- The current status and future of PD-L1 in liver cancer.
Hao L, Li S, Deng J, Li N, Yu F, Jiang Z, Zhang J, Shi X, Hu X. Hao L, et al. Front Immunol. 2023 Dec 12;14:1323581. doi: 10.3389/fimmu.2023.1323581. eCollection 2023. Front Immunol. 2023. PMID: 38155974 Free PMC article. Review. - Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma.
Jain D, Murti Y, Khan WU, Hossain R, Hossain MN, Agrawal KK, Ashraf RA, Islam MT, Janmeda P, Taheri Y, Alshehri MM, Daştan SD, Yeskaliyeva B, Kipchakbayeva A, Sharifi-Rad J, Cho WC. Jain D, et al. Oxid Med Cell Longev. 2021 Oct 31;2021:9068850. doi: 10.1155/2021/9068850. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34754365 Free PMC article. Review. - Advances in immunotherapy for hepatocellular carcinoma.
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Sangro B, et al. Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33850328 Free PMC article. Review. - Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. Ilyas SI, et al. Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):86-103. doi: 10.1002/hep.31416. Epub 2020 Nov 7. Hepatology. 2021. PMID: 32516437 Free PMC article. Review. No abstract available. - Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Afifi AM, El-Husseiny AM, Tabashy RH, Khalil MA, El-Houseini ME. Afifi AM, et al. Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3007-3013. doi: 10.31557/APJCP.2019.20.10.3007. Asian Pac J Cancer Prev. 2019. PMID: 31653148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials